The Filing Desk

Zhengye Biotechnology

ZYBT · Nasdaq · Health Care · Financials, fiscal 2022 to 2025

ZYBT · Last close · November 19, 2026
$1.52

Zhengye Biotechnology's revenue fell 37.6% to CN¥116 million in fiscal 2025. Its operating margin was −60.6%, down from 8.8% a year earlier. Free cash flow was CN¥12 million, down 55.1%. The diluted share count rose 3.7%.

Zhengye Biotechnology Holding Limited Latest fiscal year ended December 31, 2025 20-F filed April 28, 2026 · 0001213900-26-048584 Updated
Revenue
CN¥116M
37.6%
Operating margin
−60.6%
69.4 pts
Net income
−CN¥70M
CN¥11M a year earlier
Free cash flow
CN¥12M
55.1%
Return on capital
−14.9%
18.6 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Zhengye Biotechnology is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in CNY, as it reports them: they aren't converted to US dollars. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Income statement

Revenue and net income
CNY billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
CNY billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2022 to 2024, earnings per share fell 50.5% a year and net income 50.8% a year, with the share count about the same. Zhengye Biotechnology then lost money in fiscal 2025.

Diluted earnings per share
CNY per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
CNY billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
CNY billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25
Cash and short-term investments10162052
Debt incl. finance leases—908675
Net debt (negative means net cash)—746623
Net debt to EBITDA—1.1x1.6x—
Debt to equity—0.3x0.3x0.3x
Interest coverage23.2x10.2x4.1x−20.7x
Current ratio—1.3x1.3x1.1x
Quick ratio—0.9x0.9x0.8x
CNY millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
CNY billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
CNY billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
CNY billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score——3 of 9
Rule of 400.6%2.8%−27.0%
Altman Z''3.583.731.49
Accruals ratio—−6.0%−17.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positive—PassFail
Cash from operations is positivePassPassPass
Return on assets rose——Fail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Pass
Current ratio rose—PassFail
Share count didn't risePassPassFail
Gross margin roseFailFailFail
Revenue rose relative to assets——Fail
F-score——3 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Zhengye Biotechnology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Zhengye BiotechnologyFY25−37.6%−60.6%10.6%−14.9%—3
Gyre TherapeuticsFY2510.2%9.8%−0.1%9.7%−3.8x4Compare
UroGen PharmaFY2521.4%−113.7%−148.2%——2Compare
Zevra TherapeuticsFY25350.9%−59.1%−2.3%−218.8%—5Compare
ZymeworksFY2538.9%−87.3%−32.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

4 years of figures

Fiscal yearFY22FY23FY24FY25
Income statement
Revenue260212186116
Revenue growth—−18.7%−11.9%−37.6%
Gross profit1481189124
Research and development13121318
Operating income664516−70
Net income473211−70
Diluted EPS (CNY)1.020.690.25—
Diluted shares (millions)46464647
Cash flow
Cash from operations17484113
Capital expenditure277141
Free cash flow−10412712
Dividends paid2140160
Share buybacks0000
Acquisitions0000
Stock-based compensation————
Balance sheet at fiscal year end
Cash and short-term investments10162052
Debt incl. finance leases—908675
Total assets—500493436
Total liabilities—161141130
Shareholders' equity357273284250
Margins and ratios
Gross margin56.8%55.5%49.0%20.5%
Operating margin25.3%21.2%8.8%−60.6%
Net margin18.0%14.9%6.1%−60.0%
Free cash flow margin−3.8%19.3%14.7%10.6%
Rule of 40 (growth + FCF margin)—0.6%2.8%−27.0%
Return on capital——3.7%−14.9%
Return on equity——4.1%−26.1%
Return on assets——2.3%−15.0%
Net debt to EBITDA—1.1x1.6x—
CNY millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, CNY millions)
Source: Zhengye Biotechnology's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Zhengye Biotechnology.